New drug faricimab tested for hard-to-treat eye condition
NCT ID NCT07403825
First seen Feb 18, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study tests the drug faricimab in 100 people aged 50 and older who have a specific form of age-related macular degeneration (AMD) called type 2 or mixed neovascular AMD with subretinal hyperreflective material (SHRM). The main goal is to see if faricimab can clear the SHRM by week 16. Participants will receive faricimab injections, and the study is being conducted in Spain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION, AGE-RELATED are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.